# US 2025/0325652 A1 · Antigenic polypeptide and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325652 A1
- Document ID: US20250325652A1
- Status: Published application
- Kind: A1
- Application number: 18/717,765
- Filed: 2022-12-08
- Published: 2025-10-23
- Earliest claimed: 2021-12-08
- Assignees: Anda Biology Medicine Development (Shenzen) Co., Ltd.
- Applicants: Anda Biology Medicine Development (Shenzen) Co., Ltd.
- Inventors: Landian Hu
- Web page: https://patentgrep.com/patent/US20250325652A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 37/04: Immunostimulants
- G01N 33/56983: {Viruses}
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are an isolated polypeptide or an antigenic fragment thereof, an antibody binding to the isolated polypeptide or the antigenic fragment thereof, a composition including the isolated polypeptide or the antigenic fragment thereof, and an array including the isolated polypeptide or the antigenic fragment thereof. Further provided a method for detecting the presence of an antibody against SARS-COV-2 in a subject, a method for the prognosis of the subject infected with SARS-COV-2, a method for inducing an immune response against SARS-CoV-2 in a subject, and a method for preventing and/or treating a disease caused by SARS-COV-2 infection in a subject.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A composition comprising a polypeptide having an amino acid sequence shown as SEQ ID NO: 10 or an antigenic fragment thereof or an amino acid sequence obtained after a substitution, a deletion, an insertion and/or an addition of one or more amino acid residues in SEQ ID NO: 10, and one or more of polypeptides having an amino acid sequence selected from amino acid sequences shown as SEQ ID NOs: 1-9 and 11-48 or antigenic fragments thereof or an amino acid sequence obtained after a substitution, a deletion, an insertion and/or an addition of one or more amino acid residues in any one of SEQ ID NOs: 1-9 and 11-48.

### Claim 52 (depends on 51)

The composition according to claim 51, wherein the composition comprises polypeptide having the amino acid sequences selected from: a) SEQ ID NOs: 10, 7, 35, 29, 23, 30, 2, 21, and 12; b) SEQ ID NOs: 10, 12, 35, 14, 30, 2, 3, 13, and 19; c) SEQ ID NOs: 10, 35, 12, and 19; d) SEQ ID NOs: 10 and 33;e) SEQ ID NOs: 10, 32, and 15; f) SEQ ID NOs: 10, 21, 30, 15, 12, 35, 23, 19, and 20.

### Claim 53 (depends on 51)

The composition according to claim 51, wherein the antigenic fragment is at least 5 amino acids, at least 6 amino acids, at least 7 amino acids, at least 8 amino acids, at least 9 amino acids, or at least 10 amino acids in length.

### Claim 54 (depends on 51)

The composition according to claim 51, wherein the composition is a vaccine composition.

### Claim 55 (depends on 51)

An array, comprising a solid substrate and polypeptides immobilized on the solid substrate, wherein the polypeptides comprise the composition of claim 51.

### Claim 56 (depends on 55)

The array according to claim 55, wherein the polypeptides comprise at least 2, at least 3, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, or at least 35 polypeptides or antigenic fragments thereof.

### Claim 57 (depends on 56)

The array according to claim 56, wherein the polypeptides comprise a polypeptide having an amino acid sequence shown as SEQ ID NO: 10 or an antigenic fragment thereof, and one or more of polypeptide having amino acid sequences selected from amino acid sequences shown as SEQ ID NOs: 1-9 and 11-48 or antigenic fragments thereof.

### Claim 58 (depends on 57)

The array according to claim 57, wherein the polypeptides comprise amino acid sequences selected from: a) SEQ ID NOs: 10, 7, 35, 29, 23, 30, 2, 21, and 12; b) SEQ ID NOs: 10, 12, 35, 14, 30, 2, 3, 13, and 19; c) SEQ ID NOs: 10, 35, 12, and 19; d) SEQ ID NOs: 10 and 33;e) SEQ ID NOs: 10, 32, and 15; f) SEQ ID NOs: 10, 21, 30, 15, 12, 35, 23, 19, and 20.

### Claim 59

An array, comprising a solid substrate and a polypeptide immobilized on the solid substrate, wherein the polypeptide comprises at least one polypeptide having an amino acid sequence selected from a group consisting of the following amino acid sequences shown as SEQ ID NO: 40-48 or an antigenic fragment thereof or an amino acid sequence obtained after a substitution, a deletion, an insertion and/or an addition of one or more amino acid residues in any one of SEQ ID NO: 40-48.

### Claim 60 (depends on 59)

The array according to claim 59, wherein the antigenic fragment is at least 5 amino acids, at least 6 amino acids, at least 7 amino acids, at least 8 amino acids, at least 9 amino acids, or at least 10 amino acids in length.

### Claim 61 (depends on 59)

The array according to claim 59, wherein the polypeptide comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or all 9 polypeptides or antigenic fragments.

### Claim 62 (depends on 61)

The array according to claim 61, wherein the polypeptide comprises a plurality of polypeptides or antigenic fragments thereof, wherein the plurality of polypeptides or antigenic fragments thereof comprise at least one polypeptide or antigenic fragment thereof derived from a SARS-COV-2 ORF1ab polyprotein, at least one polypeptide or antigenic fragment thereof derived from a SARS-COV-2 S protein, and at least one polypeptide or antigenic fragment thereof derived from a SARS-COV-2 N protein.

### Claim 63 (depends on 55)

The array according to claim 55, wherein the polypeptide is immobilized on the solid substrate after being coupled to BSA.

### Claim 64 (depends on 55)

The array according to claim 55, wherein the array is a polypeptide chip.

### Claim 65 (depends on 55)

A method for detecting the presence of an antibody against SARS-COV-2 in a subject, comprising
(a) contacting a sample from the subject with the array according to claim 55; and
(b) detecting the presence of the antibody in the sample specifically bound to the polypeptide or the polypeptide on the array.

### Claim 66 (depends on 65)

The method according to claim 65, wherein the method is used for diagnosing whether the subject is infected with SARS-COV-2.

### Claim 67 (depends on 59)

A method for the prognosis of a subject infected with SARS-COV-2, comprising
(a) contacting a sample from the subject with the array according to claim 59; and
(b) detecting the presence of an antibody in the sample specifically bound to the polypeptide or the polypeptide on the array.

### Claim 68 (depends on 51)

A method for inducing an immune response against SARS-COV-2 in a subject, comprising administrating the composition according to claim 51 to the subject.

### Claim 69 (depends on 51)

A method for preventing and/or treating a disease caused by SARS-COV-2 infection in a subject, comprising administrating composition according to claim 51 to the subject.

### Claim 70 (depends on 69)

The method according to claim 69, wherein the composition comprise at least one polypeptide or antigenic fragment thereof derived from a SARS-COV-2 ORF1ab polyprotein, at least one polypeptide or antigenic fragment thereof derived from a SARS-COV-2 S protein, and at least one polypeptide or antigenic fragment thereof derived from a SARS-COV-2 N protein.
